G1 Therapeutics, Inc.
GTHX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.3% | -2.7% | 20.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95.6% | 92.5% | 91.6% | 75% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15.8% | -56.1% | -52% | -122.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -33.1% | -70.6% | -73.1% | -148% |
| EPS Diluted | -0.1 | -0.2 | -0.21 | -0.35 |
| % Growth | 50% | 4.8% | 40% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |